

CONTENTS

PREFACE	v
CHAPTER 1. An Introduction to Clinical Trials	1
1.1 INTRODUCTION	1
1.2 A BRIEF HISTORY OF CLINICAL TRIALS	2
1.3 TYPES OF CLINICAL TRIAL	5
1.4 ETHICS OF CLINICAL TRIALS	9
1.5 CLINICAL TRIAL PROTOCOLS	16
1.6 SUMMARY	17
CHAPTER 2. Treatment Allocation, the Size of Trials and Reporting Results	18
2.1 INTRODUCTION	18
2.2 TREATMENT ASSIGNMENT METHODS	18
2.2.1 Simple Randomisation	21
2.2.2 Blocked Randomisation	22
2.2.3 Stratified Randomisation	24
2.2.4 Minimisation Method	26
2.2.5 Unequal Randomisation	27
2.3 THE SIZE OF A CLINICAL TRIAL	29
2.4 REPORTING RESULTS	33
2.5 SUMMARY	35

CHAPTER 3. Monitoring Trial Progress: Outcome Measures, Compliance, Dropouts and Interim Analyses	37
3.1 INTRODUCTION	37
3.2 OUTCOME MEASURES	38
3.3 COMPLIANCE, DROPOUTS AND INTENTION-TO-TREAT	41
3.3.1 Intention-to-Treat	45
3.3.2 A Taxonomy of Dropouts	51
3.4 INTERIM ANALYSES IN CLINICAL TRIALS	55
3.4.1 Group Sequential Procedures — Bayesian Perspective	64
3.5 SUMMARY	67
CHAPTER 4. Basic Analyses of Clinical Trials, the Generalised Linear Model and the Economic Evaluation of Trials	69
4.1 INTRODUCTION	69
4.2 A BRIEF REVIEW OF BASIC STATISTICS	70
4.3 GENERALISED LINEAR MODELS	77
4.3.1 Models for Counts: the Treatment of Familial Adenomatous Polyposis (FAP) with a Non-Steroidal Anti-Inflammatory Drug	82
4.3.2 Ordinal Response Models: A Clinical Trial in Lymphoma	88
4.3.2.1 Models with parallel linear predictors	88
4.3.2.2 Non-parallel models	89
4.3.2.3 Model estimation	90
4.4 MULTIPLE ENDPOINTS	92
4.5 ECONOMIC EVALUATION OF TRIALS	96
4.5.1 Measuring Costs	96
4.5.2 Analysis of Cost Data	98
4.5.3 Cost-Benefit Analysis	100

4.5.4 An Example: Cognitive Behavioral Therapy	101
4.6 SUMMARY	105

CHAPTER 5. Simple Approaches to the Analysis of Longitudinal Data from Clinical Trials 107

5.1 INTRODUCTION	107
5.2 GRAPHICAL METHODS FOR DISPLAYING LONGITUDINAL DATA	108
5.3 TIME-BY-TIME ANALYSIS OF LONGITUDINAL DATA	117
5.4 RESPONSE FEATURE ANALYSIS OF LONGITUDINAL DATA	119
5.4.1 Choosing Summary Measures	120
5.4.2 Incorporating Pre-Randomisation, Baseline Measures into the Response Feature Approach . .	128
5.4.3 Response Feature Analysis when the Response Variable is Binary	132
5.5 SUMMARY	139

CHAPTER 6. Multivariate Normal Regression Models for Longitudinal Data from Clinical Trials 141

6.1 INTRODUCTION	141
6.2 SOME GENERAL COMMENTS ABOUT MODELS FOR LONGITUDINAL DATA	143
6.3 MISSING VALUES AND LIKELIHOOD-BASED INFERENCE FOR LONGITUDINAL DATA	145
6.4 MAXIMUM LIKELIHOOD ESTIMATION ASSUMING NORMALITY	147
6.5 NUMERICAL EXAMPLES	149
6.5.1 Oestrogen Patches in the Treatment of Post-Natal Depression	149
6.5.2 Post-Surgical Recovery in Young Children	156

6.6	ANOVA AND MANOVA APPROACHES TO THE ANALYSIS OF LONGITUDINAL DATA	164
6.7	INFORMATIVE DROP OUTS	165
6.8	OTHER METHODS FOR THE ANALYSIS OF LONGITUDINAL DATA	170
6.9	SUMMARY	173
CHAPTER 7. Models for Non-Normal Longitudinal Data from Clinical Trials		175
7.1	INTRODUCTION	175
7.2	MARGINAL MODELS	176
	7.2.1 Marginal Modelling using Generalised Estimating Equations	179
7.3	RANDOM EFFECTS MODELS	189
7.4	TRANSITION MODELS	193
7.5	A COMPARISON OF METHODS	196
7.6	MISSING DATA AND WEIGHTED ESTIMATING EQUATIONS	198
	7.6.1 Missing Data in a Longitudinal Clinical Trial with an Ordinal Response	199
7.7	SUMMARY	202
CHAPTER 8. Survival Analysis		203
8.1	INTRODUCTION	203
8.2	THE SURVIVOR FUNCTION AND THE HAZARD FUNCTION	204
	8.2.1 Survivor Function	204
	8.2.2 The Hazard Function	211
8.3	REGRESSION MODELS FOR SURVIVAL DATA	215
8.4	ACCELERATED FAILURE TIME MODELS	216
8.5	PROPORTIONAL HAZARDS MODEL	220
	8.5.1 Proportional Hazards	220

8.5.2	The Semi-Parametric Proportional Hazard or Cox Model	221
8.5.3	Cox Model Example	224
8.5.4	Checking the Specification of a Cox Model	227
8.5.5	Goodness-of-fit Tests	235
8.5.6	Influence	236
8.6	TIME-VARYING COVARIATES	237
8.6.1	Modelling with Time-Varying Covariates	237
8.6.2	The Problem of Internal or Endogeneous Covariates	238
8.6.3	Treatment Waiting Times	239
8.7	STRATIFICATION, MATCHING AND CLUSTER SAMPLING	240
8.7.1	Stratification	240
8.7.2	Matching	241
8.7.3	Cluster Sampling	242
8.8	CENSORING AND COMPETING RISKS	243
8.9	AUXILIARY VARIABLES	244
8.10	FRAILTY MODELS	245
8.11	INTERIM ANALYSIS FOR SURVIVAL TIME DATA	246
8.11.1	An Example of the Application of an Interim Analysis Procedure for Survival Data	246
8.12	DESCRIBING THE RESULTS OF A SURVIVAL ANALYSIS OF A CLINICAL TRIAL	248
8.13	SUMMARY	249
CHAPTER 9. Bayesian Methods Longitudinal Data		250
9.1	INTRODUCTION	250
9.2	BAYESIAN ESTIMATION	252
9.3	MARKOV CHAIN MONTE CARLO (MCMC)	255
9.4	ADVANTAGES OF THE MCMC APPROACH	256
9.4.1	Model Parametrisation and Scientific Inference . .	256
9.4.2	Missing Data	257

9.4.3	Prior Distributions as a Numerical Device	258
9.4.4	Alternative Models and Model Selection	258
9.5	A NUMERICAL EXAMPLE OF USING BAYESIAN ESTIMATION	259
9.6	INFORMATIVE PRIORS	262
9.7	PRIORS AND STOPPING RULES FOR TRIAL MONITORING	263
9.7.1	Clinical Demands	264
9.7.2	Clinical Beliefs	266
9.8	MONITORING	267
9.8.1	The Prior as a Handicap	267
9.8.2	Recognising Heterogeneity in Priors: Enthusiasts and Sceptics	268
9.9	SAMPLE SIZE ESTIMATION FOR EARLY PHASE TRIALS	270
9.10	REPORTING OF RESULTS	273
9.11	SUMMARY	273
	CHAPTER 10. Meta-Analysis	275
10.1	INTRODUCTION	275
10.2	SELECTION OF STUDIES — WHAT TO INCLUDE	277
10.3	THE STATISTICS OF META-ANALYSIS	282
10.4	TWO EXAMPLES OF THE APPLICATION OF META-ANALYSIS	290
10.4.1	The Comparison of Sodium Monofluorophosphate (SMFP) and Sodium Fluoride (NaF) Toothpastes in the Prevention of Caries Development	290
10.4.2	The Effectiveness of Aspirin in Preventing Death after a Myocardial Infarction	291
10.5	BAYESIAN META-ANALYSIS	293
10.6	META-ANALYSIS IN MORE COMPLEX SETTINGS	295
10.7	SUMMARY	295

Contents

xiii

APPENDIX A. Software

298

REFERENCES

303

INDEX

320